{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:48:00Z","timestamp":1790153280835,"version":"4.0.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC2117-422037984"],"award-info":[{"award-number":["EXC2117-422037984"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008967","name":"Philipps-Universit\u00e4t Marburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008967","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variants of the virus. This may ultimately only be possible through induction of potent and long-lasting immune responses in the nasopharyngeal tract, the initial entry site of SARS-CoV-2. To this end, we have designed a vaccine based on recombinantly expressed receptor binding domain (RBD) of SARS-CoV-2, fused to the C-terminus of\n                    <jats:italic>C. perfringens<\/jats:italic>\n                    enterotoxin, which is known to target Claudin-4, a matrix molecule highly expressed on mucosal microfold (M) cells of the nasal and bronchial-associated lymphoid tissues. To further enhance immune responses, the vaccine was adjuvanted with a novel toll-like receptor 3\/RIG-I agonist (Riboxxim\u2122), consisting of synthetic short double stranded RNA. Intranasal prime-boost immunization of mice induced robust mucosal and systemic anti-SARS-CoV-2 neutralizing antibody responses against SARS-CoV-2 strains Wuhan-Hu-1, and several variants (B.1.351\/beta, B.1.1.7\/alpha, B.1.617.2\/delta), as well as systemic T-cell responses. A combination vaccine with M-cell targeted recombinant HA1 from an H1N1 G4 influenza strain also induced mucosal and systemic antibodies against influenza. Taken together, the data show that development of an intranasal SARS-CoV-2 vaccine based on recombinant RBD adjuvanted with a TLR3 agonist is feasible, also as a combination vaccine against influenza.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-31198-3","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T12:05:43Z","timestamp":1679400343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim\u2122 elicits strong antibody and T-cell responses in mice"],"prefix":"10.1038","volume":"13","author":[{"given":"Dennis","family":"Horvath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Temperton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Mayora-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhold","family":"Horlacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Brosig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Morath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Jakobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Groettrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Hoschuetzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Rohayem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"ter Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"31198_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41541-021-00336-1","volume":"6","author":"I McDonald","year":"2021","unstructured":"McDonald, I. et al. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. npj Vaccines 6, 74 (2021).","journal-title":"npj Vaccines"},{"key":"31198_CR2","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1056\/NEJMoa2116597","volume":"386","author":"DW Eyre","year":"2022","unstructured":"Eyre, D. W. et al. Effect of covid-19 vaccination on transmission of alpha and delta variants. N. Engl. J Med. 386, 744\u2013756 (2022).","journal-title":"N. Engl. J Med."},{"key":"31198_CR3","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/s41591-021-01548-7","volume":"27","author":"KB Pouwels","year":"2021","unstructured":"Pouwels, K. B. et al. Effect of delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat. Med. 27, 2127\u20132135 (2021).","journal-title":"Nat. Med."},{"key":"31198_CR4","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1056\/NEJMoa2118946","volume":"386","author":"Y Goldberg","year":"2022","unstructured":"Goldberg, Y. et al. Protection and waning of natural and hybrid immunity to SARS-CoV-2. N. Engl. J. Med. 386, 2201\u20132212 (2022).","journal-title":"N. Engl. J. Med."},{"key":"31198_CR5","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.1038\/s41467-021-25949-x","volume":"12","author":"J Fr\u00f6berg","year":"2021","unstructured":"Fr\u00f6berg, J. et al. SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms. Nat. Commun. 12, 5621 (2021).","journal-title":"Nat. Commun."},{"key":"31198_CR6","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1016\/j.drudis.2021.07.021","volume":"26","author":"VP Chavda","year":"2021","unstructured":"Chavda, V. P., Vora, L. K., Pandya, A. K. & Patravale, V. B. Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management. Drug Discov. Today 26, 2619\u20132636 (2021).","journal-title":"Drug Discov. Today"},{"key":"31198_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.671633","volume":"8","author":"L Min","year":"2021","unstructured":"Min, L. & Sun, Q. Antibodies and vaccines target RBD of SARS-CoV-2. Front. Mol. Biosci. 8, 671633. https:\/\/doi.org\/10.3389\/fmolb.2021.671633 (2021).","journal-title":"Front. Mol. Biosci."},{"issue":"10","key":"31198_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/intimm\/dxx064","volume":"29","author":"Y Date","year":"2017","unstructured":"Date, Y. et al. NALT M cells are important for immune induction for the common mucosal immune system. Int. Immunol. 29(10), 471\u2013478. https:\/\/doi.org\/10.1093\/intimm\/dxx064 (2017).","journal-title":"Int. Immunol."},{"key":"31198_CR9","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.1016\/j.vaccine.2019.08.032","volume":"37","author":"H Lan","year":"2019","unstructured":"Lan, H., Hosomi, K. & Kunisawa, J. Clostridium perfringens enterotoxin-based protein engineering for the vaccine design and delivery system. Vaccine 37, 6232\u20136239 (2019).","journal-title":"Vaccine"},{"key":"31198_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1472-6750-12-7","volume":"12","author":"DD Lo","year":"2012","unstructured":"Lo, D. D., Ling, J. & Eckelhoefer, A. H. M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses. BMC Biotech. 12, 7 (2012).","journal-title":"BMC Biotech."},{"key":"31198_CR11","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1038\/s41598-018-21120-7","volume":"8","author":"H Suzuki","year":"2018","unstructured":"Suzuki, H. et al. Impaired airway mucociliary function reduces antigen-specific IgA immune response to immunization with a claudin-4-targeting nasal vaccine in mice. Sci. Rep. 8, 2904 (2018).","journal-title":"Sci. Rep."},{"key":"31198_CR12","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1038\/nm1213","volume":"11","author":"J Holmgren","year":"2005","unstructured":"Holmgren, J. & Czerkinsky, C. Mucosal immunity and vaccines. Nat. Med. Suppl. 11, S45\u2013S53 (2005).","journal-title":"Nat. Med. Suppl."},{"key":"31198_CR13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nri3251","volume":"12","author":"N Lycke","year":"2012","unstructured":"Lycke, N. Recent progress in mucosal vaccine development: Potential and limitations. Nat. Rev. Immunol. 12, 592\u2013605 (2012).","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"31198_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/s0169-409x(01)00197-1","volume":"9","author":"L Tengroth","year":"2014","unstructured":"Tengroth, L. et al. Functional effects of toll-like receptor (TLR)3, 7, 9, RIG-I and MDA-5 stimulation in nasal epithelial cells. PLoS One 9(6), e98239. https:\/\/doi.org\/10.1371\/journal.pone.0098239 (2014).","journal-title":"PLoS One"},{"key":"31198_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.antiviral.2018.03.005","volume":"153","author":"BA Malcolm","year":"2018","unstructured":"Malcolm, B. A. et al. PrEP-001 prophylactic effect against rhinovirus and influenza virus\u2014Results of 2 randomized trials. Antiviral Res. 153, 70\u201377 (2018).","journal-title":"Antiviral Res."},{"key":"31198_CR16","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1016\/j.vaccine.2014.07.078","volume":"32","author":"ET Overton","year":"2014","unstructured":"Overton, E. T. et al. Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans. Vaccine 32, 5490\u20135495 (2014).","journal-title":"Vaccine"},{"key":"31198_CR17","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1038\/s41467-021-23244-3","volume":"12","author":"J Koerner","year":"2021","unstructured":"Koerner, J. et al. PLGA-particle vaccine carrying TLR3\/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy. Nat. Commun. 12, 2935 (2021).","journal-title":"Nat. Commun."},{"key":"31198_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/283649","volume":"2013","author":"K Naumann","year":"2013","unstructured":"Naumann, K. et al. Activation of dendritic cells by the novel Toll-like receptor 3 agonist RGC100. Clin. Dev. Immunol. 2013, 283649 (2013).","journal-title":"Clin. Dev. Immunol."},{"key":"31198_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030237","volume":"3","author":"J ter Meulen","year":"2006","unstructured":"ter Meulen, J. et al. Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants. PLoS Med. 3, e237 (2006).","journal-title":"PLoS Med."},{"key":"31198_CR20","doi-asserted-by":"publisher","first-page":"17204","DOI":"10.1073\/pnas.1921186117","volume":"117","author":"H Sun","year":"2020","unstructured":"Sun, H. et al. Prevalent Eurasian avian-like H1N1 swine influenza virus with 2009 pandemic viral genes facilitating human infection. Proc. Natl. Acad. Sci. USA 117, 17204\u201317210 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"31198_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/s0169-409x(01)00197-1","volume":"52","author":"IM van der Lubben","year":"2008","unstructured":"van der Lubben, I. M., Verhoef, J. C., Borchard, G. & Junginger, H. E. Chitosan for mucosal vaccination. Adv. Drug. Deliv. Rev. 52(2), 139\u2013144. https:\/\/doi.org\/10.1016\/s0169-409x(01)00197-1 (2001).","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"31198_CR22","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.4236","volume":"11","author":"C Di Genova","year":"2021","unstructured":"Di Genova, C. et al. Production, titration, neutralisation and storage of SARS-CoV-2 lentiviral. Bio. Protoc. 11, e4236. https:\/\/doi.org\/10.21769\/BioProtoc.4236 (2021).","journal-title":"Bio. Protoc."},{"key":"31198_CR23","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.4236","volume":"11","author":"C Di Genova","year":"2021","unstructured":"Di Genova, C. et al. Production, titration, neutralisation, storage and lyophilisation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lentiviral pseudotypes. Bio Protoc. 11, e4236 (2021).","journal-title":"Bio Protoc."},{"key":"31198_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/mps1010008","volume":"1","author":"F Ferrara","year":"2018","unstructured":"Ferrara, F. & Temperton, N. Pseudotype neutralization assays: From laboratory bench to data analysis. Methods Protoc. 1, 8 (2018).","journal-title":"Methods Protoc."},{"key":"31198_CR25","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/S2213-2600(21)00458-6","volume":"9","author":"DM Altmann","year":"2021","unstructured":"Altmann, D. M. & Boyton, R. J. Waning immunity to SARS-CoV-2: Implications for vaccine booster strategies. Lancet Respir. Med. 9, 1356\u20131358 (2021).","journal-title":"Lancet Respir. Med."},{"key":"31198_CR26","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1056\/NEJMoa2105000","volume":"384","author":"E Hacisuleyman","year":"2021","unstructured":"Hacisuleyman, E. et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N. Engl. J. Med. 384, 2212\u20132218 (2021).","journal-title":"N. Engl. J. Med."},{"key":"31198_CR27","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-021-01413-7","volume":"27","author":"T Kustin","year":"2021","unstructured":"Kustin, T. et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat. Med. 27, 1379\u20131384 (2021).","journal-title":"Nat. Med."},{"key":"31198_CR28","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.155483","volume":"7","author":"MJ Siedner","year":"2022","unstructured":"Siedner, M. J. et al. Duration of viral shedding and culture positivity with postvaccination SARS-CoV-2 delta variant infections. JCI Insight 7, e155483 (2022).","journal-title":"JCI Insight"},{"key":"31198_CR29","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41591-021-01296-8","volume":"27","author":"N Huang","year":"2021","unstructured":"Huang, N. et al. SARS-CoV-2 infection of the oral cavity and saliva. Nat Med. 27, 892\u2013903 (2021).","journal-title":"Nat Med."},{"key":"31198_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103788","volume":"75","author":"L Azzi","year":"2022","unstructured":"Azzi, L. et al. Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. EBioMedicine 75, 103788 (2022).","journal-title":"EBioMedicine"},{"key":"31198_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744887","volume":"12","author":"RWY Chan","year":"2021","unstructured":"Chan, R. W. Y. et al. The mucosal and serological immune responses to the novel coronavirus (SARS-CoV-2) vaccines. Front. Immunol. 12, 744887 (2021).","journal-title":"Front. Immunol."},{"key":"31198_CR32","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1126\/science.add2897","volume":"377","author":"EJ Wherry","year":"2022","unstructured":"Wherry, E. J. & Barouch, D. H. T cell immunity to COVID-19 vaccines. Science 377, 821\u2013822 (2022).","journal-title":"Science"},{"key":"31198_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1473-3099(21)00648-4","volume":"22","author":"A Singanayagam","year":"2022","unstructured":"Singanayagam, A. et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: A prospective, longitudinal, cohort study. Lancet Infect. Dis. 22, 183\u2013195 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"31198_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/d41586-022-00057-y","volume":"601","author":"N Editorial","year":"2022","unstructured":"Editorial, N. COVID is here to stay: Countries must decide how to adapt. Nature 601, 165 (2022).","journal-title":"Nature"},{"key":"31198_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1126\/science.abq1841","volume":"377","author":"CJ Reynolds","year":"2022","unstructured":"Reynolds, C. J. et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science 377, 275 (2022).","journal-title":"Science"},{"key":"31198_CR36","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41541-021-00393-6","volume":"6","author":"H Kleanthous","year":"2021","unstructured":"Kleanthous, H. et al. Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. npj Vaccines 6, 128 (2021).","journal-title":"npj Vaccines"},{"key":"31198_CR37","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","volume":"183","author":"L Piccoli","year":"2020","unstructured":"Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024\u20131042 (2020).","journal-title":"Cell"},{"key":"31198_CR38","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nri1777","volume":"6","author":"MR Neutra","year":"2006","unstructured":"Neutra, M. R. & Kozlowski, P. A. Mucosal vaccines: The promise and the challenge. Nat. Rev. Immunol. 6, 148\u2013158 (2006).","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"31198_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126352","volume":"10","author":"H Suzuki","year":"2015","unstructured":"Suzuki, H. C-terminal clostridium perfringens enterotoxin-mediated antigen delivery for nasal pneumococcal vaccine. PLoS One 10(5), e0126352. https:\/\/doi.org\/10.1371\/journal.pone.0126352 (2015).","journal-title":"PLoS One"},{"key":"31198_CR40","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1164\/rccm.201011-1783OC","volume":"183","author":"P Brandtzaeg","year":"2011","unstructured":"Brandtzaeg, P. Potential of nasopharynx-associated lymphoid tissue for vaccine responses in the airways. Am. J. Respir. Crit. Care Med. 183, 1595\u20131604 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"31198_CR41","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3389\/fimmu.2019.01499","volume":"10","author":"A Dillon","year":"2019","unstructured":"Dillon, A. & Lo, D. D. M Cells: Intelligent engineering of mucosal immune surveillance. Front. Immunol. 10, 1499 (2019).","journal-title":"Front. Immunol."},{"key":"31198_CR42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00428-003-0898-8","volume":"444","author":"Y Fujimura","year":"2004","unstructured":"Fujimura, Y. et al. The role of M cells of human nasopharyngeal lymphoid tissue in influenza virus sampling. Virchows Arch. 444, 36\u201342 (2004).","journal-title":"Virchows Arch."},{"key":"31198_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.biomaterials.2018.10.041","volume":"192","author":"MA Islam","year":"2019","unstructured":"Islam, M. A. et al. M cell targeting engineered biomaterials for effective vaccination. Biomaterials 192, 75\u201394 (2019).","journal-title":"Biomaterials"},{"key":"31198_CR44","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.immuni.2010.10.007","volume":"33","author":"K Palucka","year":"2010","unstructured":"Palucka, K., Banchereau, J. & Mellman, I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 33, 464\u2013478 (2010).","journal-title":"Immunity"},{"key":"31198_CR45","doi-asserted-by":"publisher","first-page":"eabj9815","DOI":"10.1126\/sciadv.abj9815","volume":"8","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B. Sci. Adv. 8, eabj9815 (2022).","journal-title":"Sci. Adv."},{"issue":"Suppl","key":"31198_CR46","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4161\/hv.7.0.14584","volume":"7","author":"A Ainai","year":"2011","unstructured":"Ainai, A., Tashiro, M. & Hasegawa, H. Cross-protective immunity against influenza virus infections induced by intranasal vaccination together with a TLR3-mucosal adjuvant. Hum. Vaccines 7(Suppl), 174\u2013182 (2011).","journal-title":"Hum. Vaccines"},{"key":"31198_CR47","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa030595","volume":"350","author":"M Mutsch","year":"2004","unstructured":"Mutsch, M. et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell\u2019s palsy in Switzerland. N. Engl. J. Med. 350, 896\u2013903 (2004).","journal-title":"N. Engl. J. Med."},{"key":"31198_CR48","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/jmv.21824","volume":"82","author":"T Ichinohe","year":"2010","unstructured":"Ichinohe, T. et al. Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. J. Med. Virol. 82, 1754\u20131761 (2010).","journal-title":"J. Med. Virol."},{"key":"31198_CR49","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/mi.2017.48","volume":"1","author":"H Takaki","year":"2018","unstructured":"Takaki, H. et al. Toll-like receptor 3 in nasal CD103+ dendritic cells is involved in immunoglobulin A production. Mucosal Immunol. 1, 82\u201396 (2018).","journal-title":"Mucosal Immunol."},{"issue":"1","key":"31198_CR50","doi-asserted-by":"publisher","first-page":"276","DOI":"10.4049\/jimmunol.181.1.276","volume":"181","author":"W Xu","year":"2008","unstructured":"Xu, W. et al. Viral double-stranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF. J. Immunol. 181(1), 276\u2013287. https:\/\/doi.org\/10.4049\/jimmunol.181.1.276 (2008).","journal-title":"J. Immunol."},{"key":"31198_CR51","unstructured":"CDC 2020. https:\/\/www.cdc.gov\/flu\/spotlights\/2019-2020\/cdc-prepare-swine-flu.html."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31198-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31198-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31198-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T13:05:25Z","timestamp":1679403925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31198-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["31198"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-31198-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2244796\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]},"assertion":[{"value":"7 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RH, JR and JtM are inventors on a patent application relating to a M-cell targeted SARS-CoV-2 and H1-influenza virus vaccine. DH, NT, MMN, KDC, DC, AG, AB, JM, BJ, MG, and HH declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4648"}}